v3.26.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 12 Months Ended
Dec. 31, 2025
Basis of Presentation and Summary of Significant Accounting Policies [Abstract]  
Schedule of Segment Reporting

For the Year ended December 31, 2025

 

   BioBusiness
Segment		   Digital Asset
Segment		   Corporate   Consolidated 
Revenue  $
-
   $
-
   $
-
   $
-
 
                     
Operating expenses:                    
Research and development   1,632,581    
-
    
-
    1,632,581 
General and administrative   7,179,165    3,100,816    
-
    10,279,981 
Total operating expenses  $8,811,746   $3,100,816   $
-
   $11,912,562 
Loss from operations   (8,811,746)   (3,100,816)   
-
    (11,912,562)
                     
Other income (expense), net:                    
Realized gain on sale of digital assets   
-
    4,197,394    
-
    4,197,394 
Trading gains, net   
-
    97    
-
    97 
Unrealized gain on digital assets   
-
    1,812,348    
-
    1,812,348 
Change in FV of derivative   
-
         55,146    55,146 
Change in FV of warrant liability   
-
         22,377    22,377 
Interest income   
-
         107,595    107,595 
Interest expense   
-
         (283,011)   (283,011)
Foreign currency transaction loss   
-
    (521)   
-
    (521)
Total other income (expense), net  $
-
   $6,009,317   $(97,867)  $5,911,425 
Net loss  $(8,811,746)  $2,908,502   $(97,867)  $(6,001,137)